Clinical Research Papers:
Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching
Metrics: PDF 1680 views | HTML 1991 views | ?
Abstract
Bao-Hong Yuan1,*, Ru-Hong Li1,*, Wei-Ping Yuan2,*, Bang-De Xiang2,*, Ming-Hua Zheng3, Tian Yang4, Jian-Hong Zhong2 and Le-Qun Li2
1 Department of General Surgery, Yan’An Hospital Affiliated to Kunming Medical University, Kunming, China
2 Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
3 Department of Hepatology, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
4 Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
* These authors have contributed equally to this work
Correspondence to:
Jian-Hong Zhong, email:
Tian Yang, email:
Keywords: hepatocellular carcinoma, Hepatitis B virus, entecavir, HBV reactivation, liver function
Received: January 09, 2017 Accepted: January 27, 2017 Published: February 16, 2017
Abstract
The safety and efficacy of perioperative antiviral therapy for patients with hepatitis B virus related hepatocellular carcinoma and low serum levels of hepatitis B virus DNA are unknown. This retrospective study compared serum levels of hepatitis B virus DNA, liver function, morbidity, and length of hospital stay between patients who underwent hepatic resection alone and patients who received entecavir therapy before and after resection (n = 44 in each group). Propensity score matching was used to reduce confounding due to baseline differences between the groups. Hepatitis B virus reactivation during follow-up, which lasted a median of 6.1 months, occurred in one patient in the entecavir group (2.3%) and 11 patients in the resection-only group (25%; P = 0.02). Liver function, especially alanine aminotransferase levels, recovered much faster in the entecavir group. This group also showed a slightly lower rate of morbidity (P = 0.081) as well as significantly shorter overall hospital stay (20.1 ± 4.9 vs 24.9 ± 13.2 days; P = 0.028) and postoperative hospital stay (11.4 ± 1.9 vs 16.8 ± 13.1 days; P = 0.008). These results from this pilot study suggest that patients with hepatitis B virus related hepatocellular carcinoma and low levels of hepatitis B virus DNA are at risk of hepatitis B virus reactivation following resection, and that perioperative entecavir therapy can safely and effectively reduce this risk. Such therapy also appears to improve liver function and shorten hospitalization.
![Creative Commons License](/images/80x15.png)
PII: 15395